Chronic Mesenteric Ischemia, Median Arcuate Ligament Syndrome, and Mesenteric Arterial Dissection

49.1Definition and clinical presentation

Chronic mesenteric ischemia (CMI) is a clinicoradiologic diagnosis defined by symptomatic intestinal hypoperfusion and significant mesenteric arterial obstruction. Median arcuate ligament syndrome (MALS), discussed separately below, denotes compatible symptoms associated with extrinsic celiac-artery compression by the median arcuate ligament; incidental compression alone is not the syndrome European CMI · 2020 · ESVS 2025. Because the celiac artery, superior mesenteric artery (SMA), and inferior mesenteric artery (IMA) share robust collateral networks, symptomatic CMI typically reflects multivessel atherosclerotic disease Anandan 2012.

The classic presentation features:

• Postprandial abdominal pain, typically predictable in onset after eating.
• Food fear and reduced meal size.
• Unexplained weight loss.

Symptoms are suggestive rather than specific, frequently prompting extensive evaluation for functional or structural gastrointestinal disease before a vascular diagnosis is established European CMI · 2020 · Anandan 2012. Acute-on-chronic mesenteric ischemia presents with a sudden escalation in symptom severity or a new pain pattern. This presentation shifts the pathology from an elective revascularization problem to a bowel-viability emergency, requiring urgent imaging and operative evaluation Rebelo 2022.

49.2Diagnosis and anatomic evaluation

A definitive diagnosis requires symptom-anatomy correlation and exclusion of competing gastrointestinal pathology. Multidisciplinary evaluation incorporating vascular surgery, interventional radiology, gastroenterology, and dietetics optimizes case selection and nutritional assessment European CMI · 2020.

Computed tomography angiography (CTA) provides essential anatomic mapping, defining ostial origins, lesion length, calcification, distal target vessels, and collateral pathways. Mesenteric duplex ultrasound confirms hemodynamic significance. A peak systolic velocity greater than 275 cm/s in the SMA supports an anatomic stenosis greater than 70%, establishing the functional severity of the lesion European CMI · 2020 · Anandan 2012. The companion celiac-axis cutoff is a peak systolic velocity of 200 cm/s or greater, or an end-diastolic velocity above 55 cm/s, indicating celiac stenosis of 70% or greater; both vessels are interrogated because CMI is multivessel disease and the celiac artery is one of the two diagnostically pivotal targets. Frailty scoring and dietetic assessment are performed at diagnosis, as profound malnutrition embedded in the disease increases the hazard of intervention Lai 2024 · Wolk 2022.

49.3Treatment thresholds and revascularization

Intervention is indicated for symptomatic CMI confirmed by significant anatomic and hemodynamic obstruction. The SMA is the primary revascularization target. ESVS 2025 recommends revascularization of at least the SMA in multivessel occlusive disease with CMI; additional-vessel treatment is individualized because compelling comparative evidence for single- versus multivessel endovascular revascularization is lacking ESVS 2025. Incidental asymptomatic stenosis is managed conservatively, with individualized exceptions for patients planned for major abdominal surgery that may disrupt established collateral pathways European CMI · 2020. Systemic atherosclerosis medical therapy, including statin administration, antiplatelet therapy, blood-pressure control, and smoking cessation, is initiated at diagnosis Wolk 2022.

The treatment decision follows an ordered algorithm:

1. Competing gastrointestinal diagnoses are excluded and symptom-anatomy correlation is confirmed.
2. Initiate optimal medical therapy and assess nutritional status. In severe CMI, for example with severe weight loss, diarrhoea or constant pain, urgent revascularization should not be delayed in an attempt to improve nutrition (ESVS 2025, Class IIIb, level C). The guideline finds no established benefit from enteral or parenteral feeding before revascularization; this is not proof that every nutritional intervention causes harm or a universal feeding prohibition ESVS 2025.
3. Prefer an endovascular-first strategy when revascularization is indicated and anatomy is suitable (ESVS 2025, Class I, level B). Discuss the possibility of symptom recurrence and reintervention ESVS 2025.
4. Consider open revascularization in fit patients, after failed endovascular treatment, or when endovascular intervention is infeasible or contraindicated (ESVS 2025, Class IIa, level C). Select the reconstruction according to anatomy and operative risk; age or recurrent symptoms alone do not determine the procedure ESVS 2025.

49.4Median arcuate ligament syndrome

Median arcuate ligament syndrome (MALS) is a distinct entity characterized by postprandial pain, weight loss, nausea, and dynamic celiac-axis compression by the median arcuate ligament. It is most frequently diagnosed in young women. Precision anatomic evaluation requires CTA with dynamic phases, duplex assessment with respiratory variation, and celiac plexus assessment AOB Consensus 2026.

After exclusion of competing gastrointestinal causes and specialist multidisciplinary assessment, ligament release may be considered for selected symptomatic patients. ESVS 2025 permits surgical intervention (IIb, C) and a preference for laparoscopic or video-assisted retroperitoneal release (IIb, C). This low-certainty guidance does not establish randomized superiority of robotic or minimally invasive surgery, and benefit is not guaranteed European CMI · 2020 · ESVS 2025. A 2022 single-center series reported 11 laparoscopic releases, with improvement among eight survey respondents and additional interventions in two patients; it had no randomized open or robotic comparator Birkhold 2022. Persistent symptoms require reassessment rather than assuming inadequate decompression. The separate 2026 consensus on pancreaticoduodenal or gastroduodenal artery aneurysms addresses aneurysm-treatment sequencing, not the probability of pain relief in uncomplicated MALS AOB Consensus 2026.

49.5Isolated visceral artery dissection

Spontaneous isolated dissection of the SMA or celiac artery presents with acute or chronic abdominal pain mimicking occlusive ischemia. CTA distinguishes the dissection morphology from atherosclerosis. Initial management of uncomplicated isolated dissection is conservative, using antithrombotic therapy (antiplatelet or anticoagulation) and serial imaging surveillance Ullah 2019 · Zhang 2025.

Endovascular therapy is reserved for patients with persistent malperfusion, progressive symptoms, or an expanding false lumen. Open surgical reconstruction is a bailout option when endovascular techniques fail. Most conservatively managed patients demonstrate radiologic stability or resolution on follow-up imaging Ullah 2019 · Satokawa 2019.

49.6Surveillance and follow-up

Post-revascularization surveillance tracks symptoms, weight, dietary tolerance, and structural patency. Following endovascular CMI therapy, mesenteric duplex is scheduled at 1, 3, 6, and 12 months, and annually thereafter European CMI · 2020 · Yu 2022. Early detection of in-stent restenosis facilitates preemptive reintervention before symptomatic relapse and recurrent malnutrition occur.

Symptom recurrence requires careful interpretation. Renewed food fear, weight loss, and postprandial pain warrant prompt CTA and duplex imaging. Conversely, vague dyspepsia without weight loss requires gastrointestinal evaluation before presuming technical failure European CMI · 2020 · Menges 2020. Follow-up of conservatively managed visceral artery dissection relies on scheduled imaging to monitor for pseudoaneurysm formation or aneurysmal degeneration of the false lumen Ullah 2019.

49.7Areas of controversy

MALS controversies include uncertain ischemic versus neurogenic mechanisms, imperfect prediction of response, and persistent symptoms despite technically adequate release. The 2020 European guideline gives surgical release a weak GRADE 2D recommendation and advises against primary celiac stenting before ligament release (GRADE 1D). Residual compression, fixed stenosis, and nonvascular causes require reassessment before further intervention European CMI · 2020. ESVS 2025 retains selected-patient intervention and a weak preference for laparoscopic or video-assisted retroperitoneal release (both IIb, C), with specialist multidisciplinary assessment. Its discussion maintains a release-first approach; persistent symptoms with residual celiac stenosis may justify individual reassessment for revascularization ESVS 2025. Comparative outcomes between open and endovascular CMI revascularization are confounded by significant selection bias, complicating robust cost-effectiveness analyses Patel 2023 · Wolk 2022. Duplex velocity thresholds for in-stent restenosis are center-specific and lack uniformly established criteria Yu 2022. The optimal agent and duration for antithrombotic therapy in isolated visceral artery dissection remain heterogeneous across protocols Ullah 2019. The clinical implications and timing of recovery for CMI-associated intestinal dysbiosis following revascularization remain uncertain Munley 2023.

Further reading

• Diagnosis and Management of Isolated Superior Mesenteric Artery Dissection: A Systematic Review and Meta-Analysis. (2019). Isolated superior mesenteric artery dissection; not all chronic mesenteric ischemia or MALS. Ullah 2019